← Leaderboards
John Joseph Rossi
City Of Hope National Medical Center
$25,916,442
Attributed
$28,274,249
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$28,274,249 · 10
By mechanism
R01$16,633,488 · 3
R37$6,703,041 · 1
U01$2,081,161 · 1
P01$1,239,268 · 2
U19$921,291 · 1
R21$396,000 · 1
Top collaborators
- Peixuan Guo7 shared
- Henry Li6 shared
- John Cory Burnett4 shared
- Veenu Aishwarya1 shared
- Henry Qixiang Li1 shared
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyCellsHematopoietic Stem CellsHiv InfectionsIn VivoToxic EffectPharmaceutical PreparationsViralDesignAptamerT-LymphocyteInfectionHiv-1Mouse ModelVirusProgramsCombinatorialRna InterferenceBaseAcquired Immunodeficiency SyndromeHighly Active Antiretroviral TherapyGenesIn VitroProteins
Grant awards (74)
Develop novel inhaled neutralizing RNA therapeutics against COVID-19$396,000
R21 · FY2021 · AI · contact PI
Evaluation of Self-delivering FANA Antisense Oligonucleotide Lead Compounds for HIV Therapy$300,000
R43 · FY2021 · AI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$512,462
R01 · FY2019 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HV RNAS$654,174
R01 · FY2018 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$512,462
R01 · FY2018 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HV RNAS$654,174
R01 · FY2017 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$512,462
R01 · FY2017 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HV RNAS$654,174
R01 · FY2016 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$512,462
R01 · FY2016 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HV RNAS$654,174
R01 · FY2015 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$422,028
R01 · FY2015 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$411,529
R01 · FY2015 · HL · contact PI
Aptamer &Dendrimer Delivery of Zn Finger Nuclease &Homing Endonuclease mRNA &cDNA$189,758
U19 · FY2015 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HV RNAS$654,174
R01 · FY2014 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$422,028
R01 · FY2014 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$407,443
R01 · FY2014 · HL · contact PI
RNA Nanotechnology in Cancer Therapy$312,438
U01 · FY2014 · CA
Aptamer &Dendrimer Delivery of Zn Finger Nuclease &Homing Endonuclease mRNA &cDNA$174,167
U19 · FY2014 · AI · contact PI
RNA Nanotechnology in Cancer Therapy$65,142
U01 · FY2014 · CA
Combinatorial Use of Anti-HIV RNA-based Therapeutics$396,707
R01 · FY2013 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$395,569
R01 · FY2013 · HL · contact PI
RNA Nanotechnology in Cancer Therapy$374,523
U01 · FY2013 · CA
Aptamer &Dendrimer Delivery of Zn Finger Nuclease &Homing Endonuclease mRNA &cDNA$187,885
U19 · FY2013 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$426,191
R01 · FY2012 · HL · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$422,028
R01 · FY2012 · AI · contact PI
RNA Nanotechnology in Cancer Therapy$408,591
U01 · FY2012 · CA
Aptamer &Dendrimer Delivery of Zn Finger Nuclease &Homing Endonuclease mRNA &cDNA$151,637
U19 · FY2012 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HIV RNAs$671,040
R37 · FY2011 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$441,192
R01 · FY2011 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$397,910
R01 · FY2011 · HL · contact PI
RNA Nanotechnology in Cancer Therapy$356,186
U01 · FY2011 · CA
Aptamer &Dendrimer Delivery of Zn Finger Nuclease &Homing Endonuclease mRNA &cDNA$217,844
U19 · FY2011 · AI · contact PI
RNA Nanotechnology in Cancer Therapy$78,456
U01 · FY2011 · CA
Enhancing the Intracellular Functioning of anti-HIV RNAs$677,820
R37 · FY2010 · AI · contact PI
RNA Nanotechnology in Cancer Therapy$485,825
U01 · FY2010 · CA
Expression of anti-HIV siRNA in Blood Cells$397,910
R01 · FY2010 · HL · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$374,062
R01 · FY2010 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HIV RNAs$187,587
R37 · FY2010 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HIV RNAs$710,968
R37 · FY2009 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HIV RNAs$664,728
R37 · FY2009 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$397,910
R01 · FY2009 · HL · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$377,840
R01 · FY2009 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HIV RNAs$645,362
R37 · FY2008 · AI · contact PI
Expression of anti-HIV siRNA in Blood Cells$423,996
R01 · FY2008 · HL · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$377,840
R01 · FY2008 · AI · contact PI
Enhancing the Intracellular Functioning of anti-HIV RNAs$638,702
R37 · FY2007 · AI · contact PI
Combinatorial Use of Anti-HIV RNA-based Therapeutics$419,658
R01 · FY2007 · AI · contact PI
Development of Optimized siRNA Inhibition of HIV$250,475
P01 · FY2007 · AI · contact PI
Enhancing the Intracellular Functioning of HIV Ribozymes$517,635
R37 · FY2006 · AI · contact PI
Expression of anti-HIV siRNA in blood cells.$427,219
R01 · FY2006 · HL · contact PI
Combinatorial use of anti-HIV RNA-based therapeutics$299,054
R01 · FY2006 · AI · contact PI
Development of Optimized siRNA Inhibition of HIV$256,837
P01 · FY2006 · AI · contact PI
Enhancing the Intracellular Functioning of HIV Ribozymes$514,663
R37 · FY2005 · AI
Expression of anti-HIV siRNA in blood cells.$437,500
R01 · FY2005 · HL
Combinatorial use of anti-HIV RNA-based therapeutics$306,250
R01 · FY2005 · AI
Development of Optimized siRNA Inhibition of HIV$247,284
P01 · FY2005 · AI
Enhancing the Intracellular Functioning of HIV Ribozymes$499,675
R37 · FY2004 · AI
Expression of anti-HIV siRNA in blood cells.$437,500
R01 · FY2004 · HL
Combinatorial use of anti-HIV RNA-based therapeutics$306,250
R01 · FY2004 · AI
Development of Optimized siRNA Inhibition of HIV$246,835
P01 · FY2004 · AI
Enhancing the Intracellular Functioning of HIV Ribozymes$485,121
R37 · FY2003 · AI
Expression of anti-HIV siRNA in blood cells.$437,500
R01 · FY2003 · HL
Combinatorial use of anti-HIV RNA-based therapeutics$306,250
R01 · FY2003 · AI
Enhancing the Intracellular Functioning of HIV Ribozymes$489,740
R37 · FY2002 · AI
Combinatorial use of anti-HIV RNA-based therapeutics$306,250
R01 · FY2002 · AI
STABLE EXPRESSION OF THERAPEUTIC RNA IN BLOOD CELLS$0
P01 · FY2002 · AI
ENHANCING THE INTRACELLULAR FUNCTIONING OF HIV RIBOZYMES$306,536
R01 · FY2001 · AI
COMBINATORIAL USE OF CCR5 RIBOZYMES WITH ANTI HIV1 RNAS$232,390
R01 · FY2001 · AI
STABLE EXPRESSION OF THERAPEUTIC RNA IN BLOOD CELLS$0
P01 · FY2001 · AI
STABLE EXPRESSION OF THERAPEUTIC RNA IN BLOOD CELLS$0
P01 · FY2001 · AI
STABLE EXPRESSION OF THERAPEUTIC RNA IN BLOOD CELLS$0
P01 · FY2001 · AI
COMBINATORIAL USE OF CCR5 RIBOZYMES WITH ANTI HIV1 RNAS$300,621
R01 · FY2000 · AI
ENHANCING THE INTRACELLULAR FUNCTIONING OF HIV RIBOZYMES$297,609
R01 · FY2000 · AI
STABLE EXPRESSION OF THERAPEUTIC RNA IN BLOOD CELLS$237,837
P01 · FY2000 · AI